Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 11, 2020International Journal of Environmental Research and Public HealthOpen Access

Clinical and Regulatory Concerns of Biosimilars: A Review of Literature

View Full Paper
Ask AI
Bookmark
Share

Authors

VHVesa HalimiADArmond DaciUniversity of PrishtinaКNКaterina Ancevska Netkovska

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Halimi et al. (2020) studied this question.

synapsesocial.com/papers/6aad102f555e610345f493a2https://doi.org/10.3390/ijerph17165800
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease2017 · 69 citations
  2. 2The Concept of Biosimilars: From Characterization to Evolution—A Narrative Review2017 · 40 citations
  3. 3Evaluation of Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing2019 · 30 citations
  4. 4The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation2015 · 82 citations
  5. 5Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars2018 · 47 citations